骨髓间充质干细胞移植联合基因治疗缺血性脑血管病

背景：骨髓间充质干细胞移植后是否向神经细胞定向分化,不仅受细胞自身基因调控,更取决于所处外环境中各种信号的影响。目的：就骨髓间充质干细胞的生物学特性、转基因治疗缺血性脑血管病的理论依据以及动物实验和临床研究进展进行综述。方法：由第一作者应用计算机检索PubMed数据库2006年1月至2011年12月及中国期刊网全文数据库2006年1月至2011年12月有关骨髓间充质干细胞生物学特性、转基因治疗缺血性脑血管病的理论依据以及相关动物实验和临床研究的文章,英文检索词为“Bone Marrow Mesenchymal Stem Cells (BMSCs) transplant,Gene therapy,Ischemic Cerebrovascular Disease(ICD)”,中文检索词为“骨髓间充质干细胞移植,基因治疗,缺血性脑血管病”。排除重复性研究及Meta分析,共保留25篇文献进行综述。结果与结论：对缺血性脑血管病进行细胞移植和基因治疗改善神经功能是目前的研究热点。骨髓间充质干细胞是细胞基因工程治疗的良好载体,转基因培养后能高效地诱导分化为神经细胞,为移植治疗缺血性脑血管病提供细胞源。利用骨髓间充质干细胞移植联合基因治疗缺血性脑血管病已在动物模型上取得了令人瞩目的成就,临床应用还有待于进一步研究,尤其是生物安全性问题仍需进一步探索。

Bone marrow mesenchymal stem cell transplantation combined with gene therapy for treatment of ischemic cerebrovascular disease

BACKGROUND:Whether the transplanted bone marrow mesenchymal stem cells (BMSCs) can differentiate towards neural cells is regulated by cellular own genes and also depends on the influence of various signals in the external environment.OBJECTIVE:To review the biological characteristics of BMSCs, the theoretical evidence of transgenic therapy for treatment of ischemic cerebrovascular disease, and the research progress in animal experiments and clinical studies.METHODS:A computer-based online retrieval was performed by the first author in PubMed database to search the papers describing the biological characteristics of BMSCs, the theoretical evidence of transgenic therapy for treatment of ischemic cerebrovascular disease, and the research progress in animal experiments and clinical studies published in English or Chinese between January 2006 and December 2011, with the key words of bone marrow mesenchymal stem cells transplant, gene therapy, ischemic cerebrovascular disease (ICD). The repetitive studies and Meta analysis papers were excluded, and 25 papers were included in the final analysis. .RESULTS AND CONCLUSION:Cell transplantation and gene therapy for improving neurological function in treatment of ischemic cerebrovascular disease is an increasing research area. BMSCs are good vectors for cell gene engineering. After transgenic culture, BMSCs can be highly induced to differentiate into neural cells, which provide stem cells for treatment of ischemic cerebrovascular disease by cell transplantation. Great progress has been achieved in BMSCs transplantation combined with gene therapy for treatment of ischemic cerebrovascular disease. Nevertheless, its clinical application needs further investigation, in particular the problem of biological safety.